Clinical trial NCT05751356: TR128 in Patients With Advanced Solid Tumors
Official title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TR128 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Advanced Solid Tumor
Lead sponsor: Tarapeutics Science Inc.
Sponsor class: INDUSTRY
First posted: 2023-03-02
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Dose escalation and expansion
Primary purpose: TREATMENT

Brief summary: This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.

Detailed description: This phase I study of TR128 will investigate the tolerability, safety, pharmacokinetics (PK) and preliminary efficacy of TR128, and will define the maximum tolerated dose (MTD) of TR128 using 3+3 design. A dose expansion phase will identify the recommended phase 2 dose. In this clinical study, TR128 is given orally daily. A treatment cycle is defined as 28 days. Patients will receive study treatment until criteria for study termination are met. A safety follow-up visit will be conducted 28 days after the last dose of study treatment. Patients who discontinue study treatment for reasons other disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the sponsor stops the study, whichever comes first.

Adverse events (AEs) will be assessed using the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.

Tumor response will be assessed by computed tomography (CT) and /or magnetic resonance imaging (MRI) scan using RECIST1.1 criteria, assessed by the investigator.

Eligibility criteria: Inclusion Criteria:

* fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol.
* males and/or females at least 18 years old when signing the informed consent form.
* histologically or cytologically confirmed patients with advanced malignant solid tumors, eligible patients must have failed standard treatment, no standard treatment, or not suitable for standard treatment at this stage as determined by the investigator.
* measurable disease with at least one lesion amenable to response assessment per RECIST 1.1.
* eastern cooperative oncology group performance status (ECOG) ≤1 at screening.
* life expectancy of at least 3 months.
* acceptable organ function: Absolute neutrophil count(ANC)≥1.5×109/L; Platelet count(PLT)≥90×109/L; Hemoglobin(Hb)≥90 g/L; International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5×Upper limit of normal value (ULN), Activated Partial Thromboplastin Time (APTT)≤1.5×ULN ; Total bilirubin(TBIL)≤1.5×Upper limit of normal value(ULN) (≤3× ULN if there is liver involvement); Alanine aminotransferase(ALT)≤2.5×ULN and aspartate aminotransferase(AST)≤2.5×ULN (≤ 5 × ULN if there is liver involvement); Creatinine (Cr) ≤1.5×ULN or Creatinine Clearance (CCr) ≥50 ml/min (calculated by Cockcroft-Gault formula).
* fertile male and female must agree to use medically approved contraceptives during the study and within 6 months after the last dose of the study.

Exclusion Criteria:

* medical history and surgical history excluded according to the protocol.
* any previous medical treatment history exclude from the protocol.
* abnormal laboratory results exclude from the protocol.
* pregnant and lactating women (currently breast-feeding or less than six months after delivery although not breast-feeding).
* unsuitable for the study by the investigator's judgment.

Primary outcomes:
measure: Adverse Events and Serious Adverse Events
timeFrame: from the first dose to within 30 days after the last dose
measure: Dose limited toxicities
timeFrame: within 28 days after the first dose
measure: Maximum tolerated dose
timeFrame: Throughout the study for approximately 2 years
measure: Recommended phase II dose
timeFrame: Throughout the study for approximately 2 years
Secondary outcomes:
measure: AUClast
timeFrame: within 31 days after the first dose
measure: AUCinf
timeFrame: within 31 days after the first dose
measure: Cmax
timeFrame: within 31 days after the first dose
measure: Tmax
timeFrame: within 31 days after the first dose
measure: CL/F
timeFrame: within 31 days after the first dose
measure: Vz/F
timeFrame: within 31 days after the first dose
measure: Terminal half-life (T1/2)
timeFrame: within 31 days after the first dose
measure: ORR
timeFrame: throughout the study for approximately 2 years
measure: PFS
timeFrame: throughout the study for approximately 2 years
measure: DOR
timeFrame: throughout the study for approximately 2 years
measure: DCR
timeFrame: throughout the study for approximately 2 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital
state: Heilonjiang
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute&Hospital
state: Tianjin
Study officials:
affiliation: Peking University Cancer Hospital & Institute
name: Lin Shen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: